MiR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells

Nucleosides, Nucleotides and Nucleic Acids

Volumn 33, Issue 4-6, 2014, Pages 384-393

  Maftouh, Mina ^a   Avan, Amir ^a,b   Funel, Niccola ^d   Frampton, Adam E ^e   Fiuji, Hamid ^c   Pelliccioni, Serena ^d   Castellano, Leandro ^e   Galla, Valentina ^a   Peters, Godefridus J ^a   Giovannetti, Elisa ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PAYAME NOOR UNIVERSITY   (Iran)

^d UNIVERSITY OF PISA   (Italy)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

gemcitabine; invasive behavior; miR 211; Pancreatic ductal adenocarcinoma (PDAC); RRM2

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; MICRORNA; MICRORNA 211; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT 2; UNCLASSIFIED DRUG; DEOXYCYTIDINE; MIRN211 MICRORNA, HUMAN; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL CLONE; CELL FUNCTION; CELL INVASION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; MIGRATION INHIBITION; PANCREATIC CANCER CELL LINE; ANALOGS AND DERIVATIVES; CELL MOTION; DRUG EFFECTS; GENETICS; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; DEOXYCYTIDINE; DOWN-REGULATION; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE;

EID: 84903131932     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770.2014.891741     Document Type: Article

References (25)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2013, 63, 11-30.
2. Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 2010, 362, 1605-1617.
3. Giovannetti, E.; Erozenci, A.; Smit, J.; Danesi, R.; Peters, G.J. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol. 2012, 81, 103-122.
4. Elnaggar, M.; Giovannetti, E.; Peters, G.J. Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations. Curr. Pharm. Des. 2012, 18, 2811-2829.
5. Duxbury, M.S.; Ito, H.; Zinner, M.J. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004, 23, 1539-1548.
6. Fojo, T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist. Updat. 2007, 10, 59-67.
7. He, L.; Hannon, G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5, 522-531.
8. Esquela-Kerscher, A.; Slack, F.J. Oncomirs: microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6, 259-269.
9. Frampton, A.E.; Krell, J.; Giovannetti, E.; Jiao, L.R.; Stebbing, J. Role of miRNAs in the response to anticancer therapy. Pharmacogenomics 2012, 13, 1663-1666.
10. Krichevsky, A.M.; Gabriely, G. miR-21: a small multi-faceted RNA. J. Cell. Mol. Med. 2009, 13, 39-53.
11. Giovannetti, E.; Funel, N.; Peters, G.J.; Del Chiaro, M.; Erozenci, L.A.; Vasile, E.; Leon, L.G.; Pollina, L.E.; Groen, A.; Falcone, A.; Danesi, R.; Campani, D.; Verheul, H.M.; Boggi, U. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70, 4528-4538.
12. Giovannetti, E.; van der Velde, A.; Funel, N.; Vasile, E.; Perrone, V.; Leon, L.G.; De Lio, N.; Avan, A.; Caponi, S.; Pollina, L.E.; Gallá, V.; Sudo, H.; Falcone, A.; Campani, D.; Boggi, U.; Peters, G.J. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One. 2012, 7, e49145.
13. Iwamura, T.; Caffrey, T.C.; Kitamura, N.; Yamanari, H.; Setoguchi, T.; Hollingsworth, M.A. P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Cancer Res. 1997, 57, 1206-1212.
14. Michl, P.; Barth, C.; Buchholz, M.; Lerch, M.M.; Rolke, M.; Holzmann, K.; Menke, A.; Fensterer, H.; Giehl, K.; Löhr, M.; Leder, G.; Iwamura, T.; Adler, G.; Gress, T.M. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res. 2003, 63, 6265-6271.
15. Caponi, S.; Funel, N.; Frampton, A.E.; Mosca, F.; Santarpia, L.; Van der Velde, A.G.; Jiao, L.R.; De Lio, N.; Falcone, A.; Kazemier, G.; Meijer, G.A.; Verheul, H.M.; Vasile, E.; Peters, G.J.; Boggi, U.; Giovannetti, E. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann. Oncol. 2013, 24, 734-741.
16. Avan, A.; Crea, F.; Paolicchi, E.; Funel, N.; Galvani, E.; Marquez, V.E.; Honeywell, R.J.; Danesi, R.; Peters, G.J.; Giovannetti, E. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol. Cancer Ther. 2012, 11, 1735-1746.
17. Giovannetti, E.; Zucali, P.A.; Assaraf, Y.G.; Leon, L.G.; Smid, K.; Alecci, C.; Giancola, F.; Destro, A.; Gianoncelli, L.; Lorenzi, E.; Roncalli, M.; Santoro, A.; Peters, G.J. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br. J. Cancer. 2011, 105, 1542-1553.
18. Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10, 704-714.
19. Jones, S.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S.M.; Fu, B.; Lin, M.T.; Calhoun, E.S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D.R.; Hidalgo, M.; Leach, S.D.; Klein, A.P.; Jaffee, E.M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J.R.; Kern, S.E.; Hruban, R.H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008, 321, 1801-1806.
20. Liang, W.S.; Craig, D.W.; Carpten, J.; Borad, M.J.; Demeure, M.J.; Weiss, G.J.; Izatt, T.; Sinari, S.; Christoforides, A.; Aldrich, J.; Kurdoglu, A.; Barrett, M.; Phillips, L.; Benson, H.; Tembe, W.; Braggio, E.; Kiefer, J.A.; Legendre, C.; Posner, R.; Hostetter, G.H.; Baker, A.; Egan, J.B.; Han, H.; Lake, D.; Stites, E.C.; Ramanathan, R.K.; Fonseca, R.; Stewart, A.K.; Von Hoff, D. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One 2012, 7, e43192.
21. Funel, N.; Giovannetti, E.; Pollina, L.E., Del Chiaro, M.; Mosca, F.; Boggi, U.; Campani, D. Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. Expert Rev. Mol. Diagn. 2011, 11, 695-701.
22. Mazar, J.; DeYoung, K.; Khaitan, D.; Meister, E.; Almodovar, A.; Goydos, J.; Ray, A.; Perera, R.J. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One 2010, 5, e13779.
23. Asuthkar, S.; Velpula, K.K.; Chetty, C.; Gorantla, B.; Rao, J.S. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget 2012, 3, 1439-1454.
24. Fisher, S.B.; Patel, S.H.; Bagci, P.; Kooby, D.A.; El-Rayes, B.F.; Staley, C.A.; Adsay, N.V.; Maithel, S.K. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. Cancer 2013, 119, 445-453.
25. Avan, A.; Maftouh, M.; Giovannetti, E. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. Cancer 2013, 119, 2662-2663.